[go: up one dir, main page]

WO2014165190A3 - Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation - Google Patents

Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation Download PDF

Info

Publication number
WO2014165190A3
WO2014165190A3 PCT/US2014/024712 US2014024712W WO2014165190A3 WO 2014165190 A3 WO2014165190 A3 WO 2014165190A3 US 2014024712 W US2014024712 W US 2014024712W WO 2014165190 A3 WO2014165190 A3 WO 2014165190A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
docosapentaenoic acid
acid
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/024712
Other languages
English (en)
Other versions
WO2014165190A2 (fr
Inventor
Abdel Aziz FAWZY
George Bobotas
Ihor Terleckyj
Roelof Rongen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Priority to EP14779339.2A priority Critical patent/EP2986148A2/fr
Priority to JP2016501615A priority patent/JP2016512544A/ja
Priority to CA2905795A priority patent/CA2905795A1/fr
Publication of WO2014165190A2 publication Critical patent/WO2014165190A2/fr
Publication of WO2014165190A3 publication Critical patent/WO2014165190A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)

Abstract

La présente invention concerne une composition pouvant être administrée par voie orale et comprenant des acides gras comprenant de l'acide docosapentaénoïque (DPA) et de l'acide docosahexaénoïque (DHA). Ces compositions peuvent être utilisées pour le traitement ou la prophylaxie d'une variété de pathologies, notamment des pathologies hépatiques.
PCT/US2014/024712 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation Ceased WO2014165190A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP14779339.2A EP2986148A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation
JP2016501615A JP2016512544A (ja) 2013-03-13 2014-03-12 ドコサペンタエン酸を含む組成物、および使用方法
CA2905795A CA2905795A1 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaenoique et procedes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780948P 2013-03-13 2013-03-13
US61/780,948 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014165190A2 WO2014165190A2 (fr) 2014-10-09
WO2014165190A3 true WO2014165190A3 (fr) 2015-01-29

Family

ID=51537458

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2013/075740 Ceased WO2014143275A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide oméga-3-pentaénoïque et procédés d'utilisation
PCT/US2013/075704 Ceased WO2014158256A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide oméga-3 pentaénoïque et procédés d'utilisation
PCT/US2013/075661 Ceased WO2014143272A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation
PCT/US2014/024712 Ceased WO2014165190A2 (fr) 2013-03-13 2014-03-12 Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/US2013/075740 Ceased WO2014143275A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide oméga-3-pentaénoïque et procédés d'utilisation
PCT/US2013/075704 Ceased WO2014158256A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide oméga-3 pentaénoïque et procédés d'utilisation
PCT/US2013/075661 Ceased WO2014143272A1 (fr) 2013-03-13 2013-12-17 Compositions d'acide pentanoïque oméga 3 et méthodes d'utilisation

Country Status (4)

Country Link
EP (2) EP2968246A4 (fr)
JP (2) JP2016518315A (fr)
CA (2) CA2905671A1 (fr)
WO (4) WO2014143275A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180000775A1 (en) * 2014-12-15 2018-01-04 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases
CN116492339A (zh) * 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CA3023648C (fr) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Composition, et application et preparation pharmaceutique de cette derniere
WO2018146545A1 (fr) * 2017-02-09 2018-08-16 S.L.A. Pharma Ag Acide éicosapentaénoïque de pureté élevée, sous forme d'acide gras libre, permettant de réduire les taux de calprotectine fécale et d'empêcher une rechute clinique chez des patients atteints de recto-colite hémorragique
CN107006809B (zh) * 2017-04-11 2020-06-09 江南大学 一种有降血脂作用的醋洋葱制品及制备方法
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
US20220362199A1 (en) * 2019-10-25 2022-11-17 Nuseed Nutritional Us Inc. Enriched polyunsaturated fatty acid compositions
CN118993893B (zh) * 2024-08-07 2025-06-17 蓝平 一种epa衍生物及其制备方法与用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054329A1 (en) * 2005-11-17 2009-02-26 N.V. Nutricia Composition with docosapentaenoic acid
US20100062107A1 (en) * 2006-09-14 2010-03-11 Dong-Hun Yoon Glyceride oil composition from fish oil and preparation method thereof
US20130005757A1 (en) * 2009-04-29 2013-01-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1622467A1 (fr) * 2003-05-05 2006-02-08 Denofa AS Huiles de poisson a profil d'acides gras modifie, leur procede de production et leurs utilisations
EP1656839A1 (fr) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition contenant un mélange de lipide
CN101102988B (zh) * 2004-11-19 2011-12-14 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
EP1714564A1 (fr) * 2005-04-21 2006-10-25 N.V. Nutricia Méthode pour le traitement ou la prévention des insuffisances respiratoires
ES2426132T3 (es) * 2009-02-10 2013-10-21 Amarin Pharmaceuticals Ireland Limited Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
KR102118478B1 (ko) * 2009-03-09 2020-06-04 바스프 에이에스 지방산 오일 혼합물 및 계면활성제를 포함하는 조성물, 및 이의 방법 및 용도
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
US20110177061A1 (en) * 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
ES2663714T3 (es) * 2009-10-29 2018-04-16 Acasti Pharma Inc Composiciones terapéuticas concentradas en fosfolípidos
US20120302639A1 (en) * 2011-02-16 2012-11-29 Pivotal Therapeutics Inc. Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death
WO2013033618A1 (fr) * 2011-09-02 2013-03-07 Arctic Nutrition As Compositions lipidiques à forte teneur en dha
WO2013192109A1 (fr) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Compositions d'acide pentanoïque oméga-3 et leurs procédés d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054329A1 (en) * 2005-11-17 2009-02-26 N.V. Nutricia Composition with docosapentaenoic acid
US20100062107A1 (en) * 2006-09-14 2010-03-11 Dong-Hun Yoon Glyceride oil composition from fish oil and preparation method thereof
US20130005757A1 (en) * 2009-04-29 2013-01-03 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

Also Published As

Publication number Publication date
WO2014143272A1 (fr) 2014-09-18
WO2014143275A1 (fr) 2014-09-18
CA2905795A1 (fr) 2014-10-09
WO2014165190A2 (fr) 2014-10-09
CA2905671A1 (fr) 2014-09-18
EP2986148A2 (fr) 2016-02-24
EP2968246A1 (fr) 2016-01-20
WO2014158256A1 (fr) 2014-10-02
EP2968246A4 (fr) 2016-08-03
JP2016518315A (ja) 2016-06-23
JP2016512544A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
WO2014165190A3 (fr) Compositions comprenant de l'acide docosapentaénoïque et procédés d'utilisation
EP3630908A4 (fr) Nouvelles compositions d'acides modifiées en tant qu'alternatives à des acides classiques dans l'industrie pétrolière et gazière
PH12016501194B1 (en) Lipid comprising long chain polyunsaturated fatty acids
UA114615C2 (uk) Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
HK1198515A1 (en) Fatty acid compositions
ZA201704820B (en) Process for increasing the stability of a composition comprising polyunsaturated omega-3 fatty acids
ZA201704821B (en) Process for increasing the stability of a composition comprising polyunsaturated omega-6 fatty acids
EP3661600A4 (fr) Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
MX2015011767A (es) Composiciones de aceite crudo de algas.
ZA201702385B (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
PL3219316T3 (pl) Mieszanina kwasów tłuszczowych (grupa kwasów tłuszczowych f.a.g.) do zastosowania w leczeniu patologicznych stanów zapalnych
MX2021001790A (es) Composiciones solidas de trigliceridos y usos de estas.
WO2014108337A8 (fr) Carboxamides i à base de pyrazolyl à utiliser en tant qu'inhibiteurs du canal crac
HK1244218A1 (zh) 包括多不饱和游离脂肪酸的毫米胶囊配制品
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
EP3201287A4 (fr) Compositions d'acides synthétiques utilisables comme substituts d'acides classiques dans l'industrie pétrolière et gazière
EP3201288A4 (fr) Compositions d'acides synthétiques utilisables comme substituts d'acides classiques dans l'industrie pétrolière et gazière
PL3784044T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
PL3560342T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
WO2014108336A8 (fr) Carboxamides ii à base de pyrazolyle servant d'inhibiteurs de crac
EP3027180A4 (fr) Compositions et procédés de traitement de troubles du métabolisme des acides gras
EP3201286A4 (fr) Compositions d'acides synthétiques utilisables comme substituts d'acides classiques dans l'industrie pétrolière et gazière
EP3201289A4 (fr) Compositions d'acides synthétiques utilisables comme substituts d'acides classiques dans l'industrie pétrolière et gazière
EP3201290A4 (fr) Compositions d'acide synthétique utilisées en tant qu'alternative à des acides traditionnels dans l'industrie pétrolière et gazière
WO2014140934A3 (fr) Lipides naturels contenant des acides gras non oxydables

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779339

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2905795

Country of ref document: CA

Ref document number: 2016501615

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014779339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014779339

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14779339

Country of ref document: EP

Kind code of ref document: A2